- Home
- KAVL vs RDHL Comparison
KAVL vs RDHL Comparison
Compare KAVL & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KAVL
- RDHL
- Stock Information
- Founded
- KAVL 1998
- RDHL 2009
- Country
- KAVL United States
- RDHL Israel
- Employees
- KAVL N/A
- RDHL N/A
- Industry
- KAVL Medicinal Chemicals and Botanical Products
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- KAVL Health Care
- RDHL Health Care
- Exchange
- KAVL Nasdaq
- RDHL Nasdaq
- Market Cap
- KAVL 8.9M
- RDHL 8.2M
- IPO Year
- KAVL N/A
- RDHL N/A
- Fundamental
- Price
- KAVL $1.35
- RDHL $5.85
- Analyst Decision
- KAVL
- RDHL
- Analyst Count
- KAVL 0
- RDHL 0
- Target Price
- KAVL N/A
- RDHL N/A
- AVG Volume (30 Days)
- KAVL 1.2M
- RDHL 10.8K
- Earning Date
- KAVL 03-24-2025
- RDHL 08-29-2024
- Dividend Yield
- KAVL N/A
- RDHL N/A
- EPS Growth
- KAVL N/A
- RDHL N/A
- EPS
- KAVL N/A
- RDHL N/A
- Revenue
- KAVL $10,108,906.00
- RDHL $3,707,000.00
- Revenue This Year
- KAVL $652.90
- RDHL $224.90
- Revenue Next Year
- KAVL N/A
- RDHL $82.69
- P/E Ratio
- KAVL N/A
- RDHL N/A
- Revenue Growth
- KAVL N/A
- RDHL N/A
- 52 Week Low
- KAVL $0.58
- RDHL $5.41
- 52 Week High
- KAVL $9.69
- RDHL $20.28
- Technical
- Relative Strength Index (RSI)
- KAVL 60.47
- RDHL 40.71
- Support Level
- KAVL $1.13
- RDHL $5.76
- Resistance Level
- KAVL $1.45
- RDHL $6.26
- Average True Range (ATR)
- KAVL 0.18
- RDHL 0.33
- MACD
- KAVL 0.01
- RDHL 0.01
- Stochastic Oscillator
- KAVL 75.73
- RDHL 20.17
About KAVL Kaival Brands Innovations Group Inc.
Kaival Brands Innovations Group Inc is focused on growing and incubating innovative and profitable products. The company is engaged in the sale, marketing and distribution of electronic nicotine delivery system (ENDS) products and related components. Its primary product includes Bidi Stick. The BIDI Stick comes in a variety of flavor options for adult cigarette smokers.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.